^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Testicular Cancer

    Related cancers:
    20h
    Expression and significance analysis of GDF3 in testicular cancer based on TCGA and GTEx databases (PubMed, Zhonghua Nan Ke Xue)
    The GDF3 is closely related to the occurrence, development, and immune microenvironment of testicular cancer.
    Journal
    |
    ADORA2A (Adenosine A2a Receptor)
    2d
    XmAb541-01: Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=212, Recruiting, Xencor, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    3d
    Micro-RNA-371a-3p in Germ Cell Testicular Tumors on Diagnosis: A Prospective Case-Control Study in Turkish Population. (PubMed, Urol J)
    The miR-371a-3p seems to have higher diagnostic accuracy than classical serum tumor markers in GCT.
    Journal
    |
    AFP (Alpha-fetoprotein)
    3d
    Landscape of Genomic Profiling and Circulating Tumor DNA Among Rare Genitourinary Cancers (AUA 2024)
    Herein, we add to the sparce literature regarding tumor gene characteristics of rare GU malignancies. MDR testing appears to be a useful adjunct in postoperative rare GU malignancy surveillance. MDR may anticipate recurrence or progression compared to standard techniques and correlation with response to systemic therapy.
    PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase)
    |
    NF1 mutation • TERT mutation
    |
    Signatera™
    3d
    AYA STEPS: Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=260, Not yet recruiting, Duke University
    New trial
    3d
    A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review. (PubMed, Medicine (Baltimore))
    KLRB1 was highly positively correlated with natural killer cell activation in immune response and positively correlated with tumor-infiltrating immune cells. This study demonstrated for the first time the role of KLRB1 in TGCT, which may serve as a new biomarker associated with immune infiltration and provide a potential therapeutic target for the treatment of TGCT.
    Review • Journal
    |
    KLRB1 (Killer Cell Lectin Like Receptor B1)
    5d
    Familial syndromes associated with testicular and paratesticular neoplasms: a comprehensive review. (PubMed, Virchows Arch)
    Additionally, an association between testicular sex cord stromal tumors and paratesticular sarcomas with Familial adenomatous polyposis syndrome and DICER1 syndrome, respectively, has been proposed as well. This review provides a comprehensive overview of the intricate relationship between familial syndromes and associated testicular and paratesticular tumors, shedding light on their clinicopathological and molecular characteristics.
    Review • Journal
    |
    DICER1 (Dicer 1 Ribonuclease III)
    8d
    Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel (clinicaltrials.gov)
    P2, N=34, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1)
    |
    paclitaxel • Tasigna (nilotinib)
    10d
    MV: The Man Van Project (clinicaltrials.gov)
    P=N/A, N=4000, Recruiting, Royal Marsden NHS Foundation Trust
    New trial
    11d
    A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8. (PubMed, Gene)
    The JAK2 inhibitor fedratinib attenuated the oncogenic outcomes induced by DAZL overexpression, whereas silencing MCM8 counteracted the effects of DAZL overexpression on cisplatin-damaged DNA synthesis and half-maximal inhibitory concentration of cisplatin. In conclusion, DAZL was identified as a novel cancer-germline gene that enhances the translation of JAK2 and MCM8 to promote NSCLC progression and resistance to cisplatin, respectively. These findings suggest that DAZL is a potential therapeutic target in NSCLC.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    cisplatin • Inrebic (fedratinib)
    12d
    Ovarian Sex Cord Tumor Harboring FUS::CREM Fusion: An Ovarian Counterpart of Inflammatory and Nested Testicular Sex Cord Tumor. (PubMed, Am J Surg Pathol)
    No abstract available
    Journal
    |
    CREM (CAMP Responsive Element Modulator)
    15d
    A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, University of California, Irvine | Phase classification: P3 --> P=N/A
    Phase classification • Adverse events
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1R1 (Interleukin 1 receptor, type I) • CRP (C-reactive protein)
    20d
    Testicular tumours in adrenogenital syndrome. (PubMed, Ugeskr Laeger)
    Enhanced adherence restored hormone levels, promoting eugonadism. Adherence plays a crucial role in diminishing tumour size and preventing complications, potentially necessitating orchiectomy in severe cases.
    Journal
    |
    CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
    23d
    RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors. (PubMed, Life (Basel))
    They are well described in solid malignancies, where many of the involved factors are used as prognostic molecular markers or targets for precision therapy. This narrative review focused, in the first part, on PGCs' survival/proliferation and differentiation and on the genetic and epigenetic factors involved in the pathogenesis of testicular germ cell tumors (TGCTs) and, in the second part, on the most recent investigations about the KIT-RAS pathway in TGCTs and in other cancers, highlighting the efforts that are being made to identify targetable markers for precision medicine approaches.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    25d
    β-Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis. (PubMed, Histopathology)
    These results demonstrate that β-catenin alterations are relatively common in LCT, most likely occurring as subclonal events that are not enriched in cases with aggressive features. Further studies are needed to clarify the oncogenic role of β-catenin in this tumour type.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    CTNNB1 mutation
    26d
    Evolution of Testicular Germ Cell Tumors in the Molecular Era with Histogenetic Implications. (PubMed, Adv Anat Pathol)
    The GCTs are remarkably sensitive to cisplatin-based combination chemotherapy; however, resistance to cisplatin develops in up to 8% of tumors and appears to be driven by TP53/MDM2 gene mutations...The mechanisms underlying the development of most tumors have been elucidated; however, additional studies are required to pinpoint the events directing specific characteristics. Advances in identifying specific molecular markers have been seen recently and may be adopted as gold standards in the future.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • MDM2 (E3 ubiquitin protein ligase) • POU5F1 (POU Class 5 Homeobox 1)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • KIT mutation • MDM2 mutation
    |
    cisplatin
    30d
    Testicular Primary Well-Differentiated Neuroendocrine Tumor: Clinicopathologic, Immunohistochemical, and Molecular Characterization of Two Patients. (PubMed, Int J Surg Pathol)
    Considering its rarity, it may pose a diagnostic challenge or pitfall in certain clinical circumstances. In addition, the literature pertaining to this entity is herein reviewed.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • SYP (Synaptophysin)
    1m
    Prevalence of lung cysts in adolescents and adults with a germline DICER1 pathogenic/likely pathogenic variant: a report from the National Institutes of Health and International Pleuropulmonary Blastoma/DICER1 Registry. (PubMed, Thorax)
    Lung cysts are common in adolescents and adults with germline DICER1 variation. Further study is needed to understand the mechanism of non-progression or regression of lung cysts in childhood to guide judicious intervention.
    Journal
    |
    DICER1 (Dicer 1 Ribonuclease III)
    1m
    Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    topotecan • melphalan • busulfan • Neupogen (filgrastim)
    1m
    SEMS: Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma (clinicaltrials.gov)
    P=N/A, N=55, Active, not recruiting, University of Southern California | Phase classification: P2 --> P=N/A
    Phase classification • Surgery • Metastases
    |
    AFP (Alpha-fetoprotein)
    1m
    The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study. (PubMed, Cells)
    Dinaciclib, when combined with CP, could be useful for improving nonseminoma TC response to CP.
    Preclinical • Journal
    |
    CDK5 (Cyclin Dependent Kinase 5)
    |
    cisplatin • dinaciclib (MK-7965)
    1m
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (clinicaltrials.gov)
    P=N/A, N=50000, Recruiting, Massive Bio, Inc. | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • CLDN18 (Claudin 18) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • NRG1 (Neuregulin 1) • POLE (DNA Polymerase Epsilon) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VEGFA (Vascular endothelial growth factor A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PTCH1 (Patched 1) • FGFR4 (Fibroblast growth factor receptor 4) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • TSC2 (TSC complex subunit 2) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • MDM4 (The mouse double minute 4) • POLD1 (DNA Polymerase Delta 1) • CDK6 (Cyclin-dependent kinase 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • JAK3 (Janus Kinase 3) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CHEK1 (Checkpoint kinase 1) • GATA6 (GATA Binding Protein 6) • MSH3 (MutS Homolog 3) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • CSF1R (Colony stimulating factor 1 receptor) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • HDAC1 (Histone Deacetylase 1) • PRDM1 (PR/SET Domain 1) • ZNF217 (Zinc Finger Protein 217) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • PARP2 (Poly(ADP-Ribose) Polymerase 2) • PARP3 (Poly(ADP-Ribose) Polymerase Family Member 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • ACVR1B (Activin A Receptor Type 1B) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    1m
    Steroidogenic Acute Regulatory Protein Is a Useful Marker for Sex-Cord-Stroma Tumors and Normal and Neoplastic Adrenocortical Tissue. (PubMed, Arch Pathol Lab Med)
    A comparison with preexisting Melan-A (a melanocyte antigen) data revealed that StAR was more often positive in adrenocortical neoplasms and in Leydig cell tumors while StAR (but not Melan-A) was negative in Sertoli cell tumors. Our data provide a comprehensive overview on the patterns of StAR immunostaining in human tumors and suggest a diagnostic utility of StAR immunohistochemistry for supporting a diagnosis of Leydig cell tumors or of normal or neoplastic adrenocortical tissue.
    Journal • Stroma
    |
    MLANA (Melan-A) • STAR (Steroidogenic Acute Regulatory Protein)
    1m
    Utility of Circulating Tumor DNA in Patients with Different Stages of Testicular Cancer (AUA 2024)
    ctDNA status was found to be correlated with the different stages of testicular cancer. ctDNA may be used for tailoring treatment protocols to patients with negative/mildly elevated serum tumor markers and for treatment escalation/deescalation. Prospective studies with larger cohorts are necessary to validate these initial results.
    Clinical • Circulating tumor DNA
    |
    Signatera™
    1m
    A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors. (PubMed, Oncogene)
    Simultaneous expression of both genes in breast cells in vitro has a synergistic effect that increases stemness and activates a transcriptional profile also observed in double-positive tumors. Therefore, we reveal a functional cooperation between Cancer/Testis genes in basal breast tumors; these findings have consequences for the understanding, diagnosis, and therapy of the breast tumors with the worst outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • HORMAD1 (HORMA Domain Containing 1)
    |
    HER-2 positive
    1m
    Humoral immunoprofiling identifies novel biomarkers and an immune suppressive autoantibody phenotype at the site of disease in pancreatic ductal adenocarcinoma. (PubMed, Front Oncol)
    Conversely, the top IgA panel included AURKA, GAGE1, MAGEA10, PLEKHA5 and XAGE3aV1 (sensitivity, specificity, and AUC values of 1.000, 0.800, and 0.954). Assessment of antigen-specific serum autoantibody glycoforms revealed abundant sialylation on IgA in PDAC, consistent with an immune suppressive IgA response to disease.
    Journal
    |
    AURKA (Aurora kinase A) • MAGEA10 (MAGE Family Member A10) • ACVR2B (Activin A Receptor Type 2B)
    1m
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    2ms
    Cellular senescence in testicular cancer. Is there a correlation with the preoperative markers and the extent of the tumor? An experimental study. (PubMed, Arch Ital Urol Androl)
    The presence of cellular senescence was correlated with the extent of the testicular tumor in terms of tumor size as well as the preoperative level of the LDH serum marker.
    Journal
    |
    AFP (Alpha-fetoprotein)
    2ms
    Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (clinicaltrials.gov)
    P2, N=43, Completed, Gruppo Oncologico Italiano di Ricerca Clinica | Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Feb 2024 | Trial primary completion date: Oct 2023 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab)
    2ms
    MicroRNAs in Testicular Germ Cell Tumors: The Teratoma Challenge. (PubMed, Int J Mol Sci)
    However, a reliable marker for teratoma is still lacking. Future research should focus on the clinical validation and standardization of these biomarkers to fully realize their potential.
    Review • Journal
    |
    MIR375 (MicroRNA 375)
    2ms
    Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=212, Not yet recruiting, Xencor, Inc.
    New P1 trial • Metastases
    2ms
    A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing. (PubMed, Intern Med)
    Systemic chemotherapy and radiotherapy showed a temporary response, with decreased serum alpha-fetoprotein levels. We highlight this case of a prompt diagnosis by NGS of NUTC in a young individual with a rapidly progressing tumor.
    Journal
    |
    AFP (Alpha-fetoprotein) • BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    AFP elevation
    2ms
    MicroRNA-320a enhances LRWD1 expression through the AGO2/FXR1-dependent pathway to affect cell behaviors and the oxidative stress response in human testicular embryonic carcinoma cells. (PubMed, Aging (Albany NY))
    This is the first study showing the role of miR-320a in upregulating the testicular cancer-specific regulator LRWD1 and the importance of the AGO2/FXR1 complex in miR-320a-mediated upregulation of LRWD1 during testicular cancer progression.
    Journal
    |
    MIR320A (MicroRNA 320a) • LRWD1 (Leucine Rich Repeats And WD Repeat Domain Containing 1)
    2ms
    Retroperitoneal Sarcomatoid Yolk Sac Tumor in a Chemotherapy-Naive Patient With Testicular Postpubertal Type Teratoma: A Rare Case Report With Emphasis on Molecular Features. (PubMed, Int J Surg Pathol)
    Therefore, relevant clinicoradiologic information and ancillary work up, including immunohistochemistry and molecular studies, may be helpful for the accurate classification. Our tumor further raises awareness of this rare event, expands the spectrum of its clinical presentation, and explores the molecular features.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • GPC3 (Glypican 3) • ARAF (A-Raf Proto-Oncogene) • SALL4 (Spalt Like Transcription Factor 4)
    |
    MYC amplification
    2ms
    STARTER: Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients (clinicaltrials.gov)
    P=N/A, N=236, Not yet recruiting, Centre Leon Berard | Phase classification: P3 --> P=N/A | Trial completion date: Nov 2036 --> Nov 2037 | Trial primary completion date: Jul 2029 --> Jul 2030
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    2ms
    New analysis of atypical spermatocytic tumours reveals extensive heterogeneity and plasticity of germ cell tumours†. (PubMed, J Pathol)
    © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    2ms
    IN-FACT-0: Pilot Study of Internet-Delivered Psychological Treatment for Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=48, Recruiting, Karolinska Institutet | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial completion date • Trial primary completion date
    2ms
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
    P2, N=224, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    GETUG 13: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors (clinicaltrials.gov)
    P3, N=263, Active, not recruiting, UNICANCER | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    AFP (Alpha-fetoprotein)
    |
    cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin
    2ms
    Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer (clinicaltrials.gov)
    P2, N=14, Terminated, University Hospital, Akershus | N=29 --> 14 | Recruiting --> Terminated; Insufficient recruitment
    Enrollment change • Trial termination
    |
    cisplatin • cabazitaxel
    2ms
    Multiple bronchial carcinoids associated with Cowden syndrome. (PubMed, Endocrine)
    Our patient is the first published case of Cowden syndrome, associated with multifocal pulmonary carcinoids. Besides multiple endocrine neoplasia type 1, we propose Cowden syndrome as another hereditary condition predisposing to multiple pulmonary tumorlets and carcinoid tumours.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • SSTR (Somatostatin Receptor)
    |
    PTEN mutation
    2ms
    Therapeutic approaches to sinonasal NUT carcinoma: a systematic review. (PubMed, Eur Arch Otorhinolaryngol)
    Basing on the existing literature, a standardized line in the treatment of SNUTC is not yet well delineated. A self-personalized strategy of therapy should be drawn on each patient affected by SNUTC.
    Review • Journal
    |
    NUTM1 (NUT Midline Carcinoma Family Member 1)